Actinium Pharmaceuticals (ATNM) Competitors $1.71 -0.02 (-1.16%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$1.71 0.00 (0.00%) As of 09/3/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATNM vs. KRRO, CRGX, LYEL, TLSA, MNPR, ACRS, IMRX, TRDA, HRTX, and ACIUShould you be buying Actinium Pharmaceuticals stock or one of its competitors? The main competitors of Actinium Pharmaceuticals include Korro Bio (KRRO), CARGO Therapeutics (CRGX), Lyell Immunopharma (LYEL), Tiziana Life Sciences (TLSA), Monopar Therapeutics (MNPR), Aclaris Therapeutics (ACRS), Immuneering (IMRX), Entrada Therapeutics (TRDA), Heron Therapeutics (HRTX), and AC Immune (ACIU). These companies are all part of the "pharmaceutical products" industry. Actinium Pharmaceuticals vs. Its Competitors Korro Bio CARGO Therapeutics Lyell Immunopharma Tiziana Life Sciences Monopar Therapeutics Aclaris Therapeutics Immuneering Entrada Therapeutics Heron Therapeutics AC Immune Korro Bio (NASDAQ:KRRO) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk. Which has higher valuation and earnings, KRRO or ATNM? Actinium Pharmaceuticals has lower revenue, but higher earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKorro Bio$2.27M107.67-$83.58M-$9.75-2.67Actinium PharmaceuticalsN/AN/A-$48.82M-$1.31-1.31 Is KRRO or ATNM more profitable? Korro Bio's return on equity of -61.51% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Korro BioN/A -61.51% -42.87% Actinium Pharmaceuticals N/A -100.85%-47.89% Do insiders and institutionals have more ownership in KRRO or ATNM? 13.2% of Korro Bio shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 4.6% of Korro Bio shares are owned by insiders. Comparatively, 6.0% of Actinium Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend KRRO or ATNM? Korro Bio currently has a consensus target price of $86.83, suggesting a potential upside of 233.59%. Actinium Pharmaceuticals has a consensus target price of $4.50, suggesting a potential upside of 163.16%. Given Korro Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Korro Bio is more favorable than Actinium Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Korro Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Actinium Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to KRRO or ATNM? In the previous week, Korro Bio had 4 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 5 mentions for Korro Bio and 1 mentions for Actinium Pharmaceuticals. Korro Bio's average media sentiment score of 1.40 beat Actinium Pharmaceuticals' score of 0.00 indicating that Korro Bio is being referred to more favorably in the media. Company Overall Sentiment Korro Bio Positive Actinium Pharmaceuticals Neutral Which has more risk and volatility, KRRO or ATNM? Korro Bio has a beta of 2.66, indicating that its stock price is 166% more volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of -0.3, indicating that its stock price is 130% less volatile than the S&P 500. SummaryKorro Bio beats Actinium Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get Actinium Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNM vs. The Competition Export to ExcelMetricActinium PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$53.35M$832.18M$5.77B$21.33BDividend YieldN/A4.84%6.66%3.49%P/E Ratio-1.231.1082.3829.14Price / SalesN/A26.60498.4347.14Price / CashN/A19.5625.7018.29Price / Book1.316.5711.055.30Net Income-$48.82M-$5.07M$3.28B$998.51M7 Day Performance-1.72%0.05%0.12%-0.63%1 Month Performance3.01%10.08%8.96%4.90%1 Year Performance-5.00%25.34%53.91%13.95% Actinium Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNMActinium Pharmaceuticals1.8966 of 5 stars$1.71-1.2%$4.50+163.2%-8.6%$53.35MN/A-1.2330Short Interest ↑KRROKorro Bio1.7909 of 5 stars$23.08-2.5%$86.83+276.2%-41.3%$216.74M$2.27M-2.3770Positive NewsCRGXCARGO Therapeutics2.1177 of 5 stars$4.47flat$15.40+244.5%N/A$216.17MN/A-0.96116LYELLyell Immunopharma3.6534 of 5 stars$11.08-0.2%$15.00+35.4%-59.2%$212.86M$60K-0.46270News CoverageAnalyst UpgradeShort Interest ↓TLSATiziana Life Sciences0.2749 of 5 stars$1.81-1.1%N/A+86.2%$211.49MN/A0.008MNPRMonopar Therapeutics3.4962 of 5 stars$34.15-5.3%$66.00+93.3%+1,421.4%$210.70MN/A-10.2610News CoverageAnalyst ForecastGap UpACRSAclaris Therapeutics2.91 of 5 stars$1.93+4.9%$8.71+351.5%+79.1%$209.08M$18.72M-1.41100News CoverageIMRXImmuneering2.9645 of 5 stars$5.75+2.7%$13.00+126.1%+343.8%$208.83M$320K-3.0460Gap DownTRDAEntrada Therapeutics2.6216 of 5 stars$5.47-3.2%$25.67+369.2%-66.0%$208.06M$210.78M-3.07110HRTXHeron Therapeutics4.3089 of 5 stars$1.35-2.9%$4.50+233.3%-23.1%$206.94M$144.29M-67.50300Positive NewsACIUAC Immune1.959 of 5 stars$2.04-0.5%$12.00+488.2%-26.1%$204.84M$31.02M-3.52140Positive News Related Companies and Tools Related Companies Korro Bio Alternatives CARGO Therapeutics Alternatives Lyell Immunopharma Alternatives Tiziana Life Sciences Alternatives Monopar Therapeutics Alternatives Aclaris Therapeutics Alternatives Immuneering Alternatives Entrada Therapeutics Alternatives Heron Therapeutics Alternatives AC Immune Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ATNM) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
